Modality
small molecule (oral)
Mechanism
JAK1-selective inhibitor
Targets
JAK1
Storage
room temperature
Approved
atopic dermatitis — FDA 2022
In trial
alopecia areata, hidradenitis suppurativa, vitiligo
Black-box warnings
serious infections; mortality; malignancy; MACE; thrombosis
Pregnancy
avoid
Monitoring
TB, HBV/HCV/HIV, CBC, lipids, LFTs, lymphocytes
Sources
Last verified
2026-04-14
Mechanism of action
Rinvoq label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug
Monitoring & workup
Baseline workup
- •TB IGRA (or PPD)
- •HBV sAg + core Ab; HCV Ab
- •CBC with differential
- •CMP (creatinine, LFTs)
- •Fasting lipid panel
- •HCG if female of childbearing potential
- •Update age-appropriate vaccines (no live vaccines once started)
Ongoing monitoring
- •CBC + LFT at 4 weeks, then every 3 months
- •Lipid panel at week 12 then annually
- •Watch for herpes zoster, VTE, serious infection, MACE (class BBW)